Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

被引：0
|
作者：
Heinrich, Michael C.
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Kerstein, David
Conlan, Maureen G.
George, Suzanne
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA
[3] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[5] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[6] Ariad Pharmaceut Inc, Cambridge, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
    Serrano, Cesar
    Leal, Alessandro
    Kuang, Yanan
    Morgan, Jeffrey A.
    Barysauskas, Constance M.
    Phallen, Jillian
    Triplett, Olivia
    Marino-Enriquez, Adrian
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud P.
    Fletcher, Jonathan A.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7287 - 7293
  • [42] The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
    Piotr Rutkowski
    Elżbieta Bylina
    Anna Klimczak
    Tomasz Świtaj
    Sławomir Falkowski
    Jacek Kroc
    Iwona Ługowska
    Magdalena Brzeskwiniewicz
    Wojciech Melerowicz
    Czesław Osuch
    Ewa Mierzejewska
    Kacper Wasielewski
    Agnieszka Woźniak
    Urszula Grzesiakowska
    Zbigniew I Nowecki
    Janusz A Siedlecki
    Janusz Limon
    BMC Cancer, 12
  • [43] The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
    Rutkowski, Piotr
    Bylina, Elzbieta
    Klimczak, Anna
    Switaj, Tomasz
    Falkowski, Slawomir
    Kroc, Jacek
    Lugowska, Iwona
    Brzeskwiniewicz, Magdalena
    Melerowicz, Wojciech
    Osuch, Czeslaw
    Mierzejewska, Ewa
    Wasielewski, Kacper
    Wozniak, Agnieszka
    Grzesiakowska, Urszula
    Nowecki, Zbigniew I.
    Siedlecki, Janusz A.
    Limon, Janusz
    BMC CANCER, 2012, 12
  • [44] Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study
    Jones, Jeffrey
    Andritsos, Leslie
    Kreitman, Robert J.
    Ravandi, Farhad
    Schiffer, Charles
    Call, Timothy G.
    Lozanski, Gerard
    Harris, Pamela
    Sexton, Jennifer
    Ruppert, Amy S.
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [45] Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    Mcdonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 439 - 449
  • [46] Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden
    Langenberg, S. M. C. H.
    Reyners, A. K. L.
    Wymenga, A. N. M.
    Sieling, G. C. M.
    Veldhoven, C. M. M.
    van Herpen, C. M. L.
    Prins, J. B.
    van der Graaf, W. T. A.
    ACTA ONCOLOGICA, 2019, 58 (02) : 191 - 199
  • [47] A phase I study of nilotinib alone and in combination with imatinib in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (GIST) -: Study update
    Reichardt, Peter
    Casali, Paolo G.
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    Tanaka, Chiaki
    Jalaluddin, Muhammad
    Veronese, Maria Luisa
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [48] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [49] Regorafenib - the efficacy and safety in the treatment of the advanced gastrointestinal stromal tumors after failure in treatment with imatynib and sorafenib - the summary and a disscussion of the phase III trial
    Stepniak, Joanna
    Rutkowski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (04): : 192 - 195
  • [50] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345